- Home
- TNFA vs SVRE Comparison
TNFA vs SVRE Comparison
Compare TNFA & SVRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNFA
- SVRE
- Stock Information
- Founded
- TNFA 2014
- SVRE 2014
- Country
- TNFA United States
- SVRE Israel
- Employees
- TNFA N/A
- SVRE N/A
- Industry
- TNFA
- SVRE
- Sector
- TNFA
- SVRE
- Exchange
- TNFA NYSE
- SVRE Nasdaq
- Market Cap
- TNFA 760.1K
- SVRE 883.2K
- IPO Year
- TNFA N/A
- SVRE 2022
- Fundamental
- Price
- TNFA $0.17
- SVRE $1.20
- Analyst Decision
- TNFA
- SVRE
- Analyst Count
- TNFA 0
- SVRE 0
- Target Price
- TNFA N/A
- SVRE N/A
- AVG Volume (30 Days)
- TNFA 3.4M
- SVRE 132.6K
- Earning Date
- TNFA 05-15-2025
- SVRE 03-21-2025
- Dividend Yield
- TNFA N/A
- SVRE N/A
- EPS Growth
- TNFA N/A
- SVRE N/A
- EPS
- TNFA N/A
- SVRE N/A
- Revenue
- TNFA N/A
- SVRE $462,071.00
- Revenue This Year
- TNFA N/A
- SVRE $458.76
- Revenue Next Year
- TNFA N/A
- SVRE $106.57
- P/E Ratio
- TNFA N/A
- SVRE N/A
- Revenue Growth
- TNFA N/A
- SVRE N/A
- 52 Week Low
- TNFA $0.15
- SVRE $1.11
- 52 Week High
- TNFA $2.24
- SVRE $143.96
- Technical
- Relative Strength Index (RSI)
- TNFA 41.80
- SVRE 34.62
- Support Level
- TNFA $0.16
- SVRE $1.11
- Resistance Level
- TNFA $0.19
- SVRE $1.36
- Average True Range (ATR)
- TNFA 0.02
- SVRE 0.10
- MACD
- TNFA 0.00
- SVRE 0.03
- Stochastic Oscillator
- TNFA 29.31
- SVRE 29.03
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.